Key Highlights

● Stryker fell sharply on Friday, October 30, 2026, as health care rose.

● Revenue of $6.52 billion missed the $6.61 billion estimate.

● Adjusted Earnings of $3.52 a share missed the $3.55 estimate.

● The company cut its full-year 2026 organic growth guidance.

Stryker (NYSE:SYK) slid on Friday, October 30, 2026, after its third-quarter report disappointed investors. Reports differed on the size of the decline, but the shares fell sharply on a day when much of the health care sector was rising.

Stryker reported Revenue of $6.52 billion, below the $6.61 billion analysts expected, and adjusted earnings of $3.52 a share, a penny under the $3.55 estimate. The miss on both revenue and earnings stood out for one of the largest makers of orthopedic implants and surgical equipment.

A lower growth outlook

The bigger issue was the outlook. Stryker cut its full-year 2026 organic growth guidance, setting a range below the midpoint of its earlier forecast. Its earnings guidance of $14.80 to $14.90 a share also trailed the $14.95 consensus.

The guidance cut suggested that some of Stryker's markets are cooling. Canaccord pointed to exactly that when it downgraded the shares to Hold from Buy, with a $300 price target, citing a slowdown in hip and knee markets, according to market data.

Canaccord was not alone in turning more cautious. Raymond James cut its price target to $323, Citizens lowered its target to $390 and Needham reduced its target to $359. TD Cowen, RBC and BMO also cut their price targets, according to market data.

The string of cuts followed both the weaker-than-expected quarter and the lower outlook.

Against the grain of health care

Stryker's decline was notable because health care was one of the market's few bright spots. The sector hit a record high, according to market data, as investors rotated out of technology and into defensive stocks. Regeneron Pharmaceuticals (NASDAQ:REGN) was the S&P 500's top gainer, and Eli Lilly (NYSE:LLY), Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) all hit 52-week highs.

Stryker was not the only medical company to struggle. Illumina (NASDAQ:ILMN) fell steeply after its own third-quarter revenue came in below consensus.

The broader market had a rough day. The S&P 500 fell 140.32 points to 7,580.07, the Dow Jones Industrial Average dropped 572.25 points to 51,770.31 and the Nasdaq Composite slid 747.73 points to 25,437.00, its worst session since June. The Russell 2000 fell 47.37 points to 2,811.84.

The damage was led by technology, after Intel (NASDAQ:INTC)'s weak outlook and cash-burn warning set off a selloff in chip and AI stocks. Oil above $100 a barrel, a reported $6.3 billion hack at crypto exchange Binance and expectations of a December rate increase from the Federal Reserve also weighed on sentiment. Energy, consumer staples, utilities and health care were among the six S&P 500 sectors that rose.

The earnings bar

Strategists say investors are punishing any stumble this earnings season. "The earnings bar is very high," an Investment strategist said. A senior market strategist said on Thursday that "investors are becoming more discerning following earnings."

What to watch

Investors will be watching for any further commentary from Stryker on Demand in its hip and knee businesses, the area Canaccord flagged. Signs that the slowdown is broadening across orthopedics could weigh on peers as well.

On the macro front, the midterm elections take place on November 3, and the October jobs report arrives on Friday, November 6. Pfizer reports on Tuesday, November 3, offering another read on the health care sector's momentum.